iSpecimen Inc. OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax
iSpecimen Inc. (ISPC) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax of -$840 for the 12-month period ending 2024-12-31, per its 10-K filed 2026-04-01.
Financial Statements › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax · last filed 2026-04-01
- iSpecimen Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2024-06-30 was -$41.00.
- iSpecimen Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2024-03-31 was -$799.00.
- iSpecimen Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2024 was -$840.00.
| Period end | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 3 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 6 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 12 month |
|---|---|---|---|
| 2024-12-31 | -$840.00 10-K · filed 2026-04-01 | ||
| 2024-06-30 | -$41.00 10-Q · filed 2025-11-17 | -$840.00 derived: sum of 2 quarters · filed 2025-11-17 | |
| 2024-03-31 | -$799.00 10-Q · filed 2025-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |